Adaptive Biotechnologies (ADPT) Form 4 shows 79,590-share sale by CPO

Q: Who is the insider in this Adaptive Biotechnologies (ADPT) Form 4 filing?

The insider is Francis Lo , who serves as Chief People Officer of Adaptive Biotechnologies Corp.

Q: What stock transactions did Francis Lo report for Adaptive Biotechnologies (ADPT)?

On January 12, 2026 , Francis Lo exercised multiple stock options to acquire common shares and sold 79,590 shares of Adaptive Biotechnologies common stock.

Q: At what price were Adaptive Biotechnologies (ADPT) shares sold in this Form 4?

The Form 4 reports a sale of 79,590 shares of Adaptive Biotechnologies common stock at a price of $17.73 per share.

Q: What option exercise prices are disclosed in this Adaptive Biotechnologies (ADPT) Form 4?

The Form 4 shows stock option exercises for 36,650 shares at $7.80 , 7,723 shares at $12.14 , 21,002 shares at $8.46 , and 14,215 shares at $3.99 per share.

Q: What do the footnotes say about the vesting of Adaptive Biotechnologies (ADPT) stock options?

The footnotes state that one option grant is fully vested and exercisable , and other grants vested 1/4 on March 4, 2023, 2024, and 2025, with 1/48 of the shares vesting monthly thereafter until fully vested.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and a share sale in company stock. On January 12, 2026, Lo exercised several stock options, acquiring 36,650 shares at $7.80, 7,723 shares at $12.14, 21,002 shares at $8.46, and 14,215 shares at $3.99 per share. The same day, Lo sold 79,590 shares of common stock at $17.73 per share. After these transactions, Lo directly owned 315,978 shares of common stock and indirectly owned 2,500 shares through a spouse. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, and that the reported options are fully or time-vested according to their respective vesting schedules.

Insider Trade Summary

Net Seller: 79,590 shares ($1,411,131)

Net Sell 10 txns

Insider LO FRANCIS

Role Chief People Officer

Sold 79,590 shs ($1.41M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	36,650	$0.00	--
Exercise	Stock Option (right to buy)	7,723	$0.00	--
Exercise	Stock Option (right to buy)	21,002	$0.00	--
Exercise	Stock Option (right to buy)	14,215	$0.00	--
Exercise	Common Stock	36,650	$7.80	$286K
Exercise	Common Stock	7,723	$12.14	$94K
Exercise	Common Stock	21,002	$8.46	$178K
Exercise	Common Stock	14,215	$3.99	$57K
Sale	Common Stock	79,590	$17.73	$1.41M
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 75,500 shares (Direct); Common Stock — 352,628 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The option is fully vested and exercisable. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Form 4 Insider Transactions: What Each Field Means →

01/14/2026 - 07:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LO FRANCIS

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE

98109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/12/2026		M⁽¹⁾		36,650	A	$7.8	352,628	D
Common Stock	01/12/2026		M⁽¹⁾		7,723	A	$12.14	360,351	D
Common Stock	01/12/2026		M⁽¹⁾		21,002	A	$8.46	381,353	D
Common Stock	01/12/2026		M⁽¹⁾		14,215	A	$3.99	395,568	D
Common Stock	01/12/2026		S⁽¹⁾		79,590⁽¹⁾	D	$17.73	315,978	D
Common Stock								2,500	I	By You Jin Lee (spouse)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.8	01/12/2026		M⁽¹⁾			36,650	⁽²⁾	05/06/2029	Common Stock	36,650	$0	75,500	D
Stock Option (right to buy)	$12.14	01/12/2026		M⁽¹⁾			7,723	⁽³⁾	03/04/2032	Common Stock	7,723	$0	177,615	D
Stock Option (right to buy)	$8.46	01/12/2026		M⁽¹⁾			21,002	⁽⁴⁾	03/06/2033	Common Stock	21,002	$0	87,074	D
Stock Option (right to buy)	$3.99	01/12/2026		M⁽¹⁾			14,215	⁽⁵⁾	03/04/2034	Common Stock	14,215	$0	90,641	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

2. The option is fully vested and exercisable.

3. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

4. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

5. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in this Adaptive Biotechnologies (ADPT) Form 4 filing?

The insider is Francis Lo, who serves as Chief People Officer of Adaptive Biotechnologies Corp.

What stock transactions did Francis Lo report for Adaptive Biotechnologies (ADPT)?

On January 12, 2026, Francis Lo exercised multiple stock options to acquire common shares and sold 79,590 shares of Adaptive Biotechnologies common stock.

At what price were Adaptive Biotechnologies (ADPT) shares sold in this Form 4?

The Form 4 reports a sale of 79,590 shares of Adaptive Biotechnologies common stock at a price of $17.73 per share.

How many Adaptive Biotechnologies (ADPT) shares does Francis Lo own after the reported transactions?

Following the reported transactions, Francis Lo directly owned 315,978 shares of Adaptive Biotechnologies common stock and indirectly owned 2,500 shares through a spouse.

Were the Adaptive Biotechnologies (ADPT) insider trades made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Francis Lo on September 15, 2025.

What option exercise prices are disclosed in this Adaptive Biotechnologies (ADPT) Form 4?

The Form 4 shows stock option exercises for 36,650 shares at $7.80, 7,723 shares at $12.14, 21,002 shares at $8.46, and 14,215 shares at $3.99 per share.

What do the footnotes say about the vesting of Adaptive Biotechnologies (ADPT) stock options?

The footnotes state that one option grant is fully vested and exercisable, and other grants vested 1/4 on March 4, 2023, 2024, and 2025, with 1/48 of the shares vesting monthly thereafter until fully vested.